FIELD: medicine; immunology.
SUBSTANCE: group of inventions is intended for treating a disease mediated by type 5 CXC chemokine receptor. Antibody formulation suitable for subcutaneous administration to a patient and used for treating type 5 CXC chemokine receptor mediated disease, contains an antibody, a citrate buffer, polysorbate 20 or polysorbate 80, arginine and sucrose. Components are used in the declared amounts, and the pH value of the composition is approximately 6. Antibody is a fully human anti-CXCR5 antibody, containing a heavy chain with the amino acid sequence SEQ ID NO: 33 and light chain with amino acid sequence SEQ ID NO: 32. In other embodiments, containers and kits comprising said composition are provided. Also disclosed is a method of treating rheumatoid arthritis, involving administering to a subject in need thereof a therapeutically effective amount of said antibody composition.
EFFECT: use of the group of the invention provides prolonged stability of the antibody formulations during storage in glass containers.
13 cl, 9 tbl, 2 ex, 20 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS BASED ON BISPECIFIC ANTIBODIES TO IL-4/IL-13 | 2014 |
|
RU2690850C2 |
| STABLE BINDING PREPARATIONS BASED ON IgG4 | 2013 |
|
RU2644214C2 |
| STABLE AQUEOUS COMPOSITIONS BASED ON ANTIBODIES | 2014 |
|
RU2763787C2 |
| ANTIBODIES AGAINST CXCR5, THEIR COMPOSITIONS AND USE | 2018 |
|
RU2798422C2 |
| COMBINED FORMULATIONS OF ANTI-LAG3 ANTIBODY AND ANTI-PD-1 ANTIBODY | 2019 |
|
RU2822192C2 |
| HUMANIZED IMMUNE BODIES FOR CXCR5, THEIR SECONDARIES, AND THEIR USE | 2008 |
|
RU2571515C2 |
| STABLE COMPOSITIONS OF ANTIBODIES AGAINST PROGRAMMABLE DEATH RECEPTOR OF PD-1 PERSON AND RELATED TREATMENT | 2012 |
|
RU2633509C2 |
| ANTIBODY FORMULATIONS | 2012 |
|
RU2665810C2 |
| ANTIBODY COMPOSITION | 2015 |
|
RU2743681C2 |
| STABILISED COMPOISITONS, CONTAINING ANTIBODIES TO INTERLEUKINE 6 (IL-6R) RECEPTOR | 2011 |
|
RU2554779C2 |
